The health service in Scotland could be "overwhelmed" by rising cancer cases, a charity has warned, as it said the number of Scots diagnosed with the disease each year could top 42,000 in less than two decades.
The health charity released the figures ahead of World Cancer Day on February 4. And it said that while cancer survival rates have improved for many forms of the disease, an increase in the age of patients means more people with a higher risk will develop the disease, and that more survivors will need follow-up care, with more patients left with complex needs.
Top news stories today Prof Swanton added: "I'm hopeful that through investment and reform in the health service and advancements in research, future numbers of cancer cases might not be as high as these projections warn. But if the Scottish Government doesn't act now to prepare for this demand, there's a risk that our hard-fought progress in cancer survival could go into reverse.
Cancer Research UK's senior external affairs manager for Scotland, Andy Glyde, urged: "Years of chronic shortages in staff and equipment in cancer services must be addressed to cope with demand today and in the future. The Scottish Government's forthcoming cancer strategy must set out how we can transform the way we detect, diagnose and treat cancer to ultimately save more lives.
We have summarized this news so that you can read it quickly. If you are interested in the news, you can read the full text here. Read more:
United Kingdom Latest News, United Kingdom Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Aspirin increases chemosensitivity of colorectal cancer cells and inhibits the expression of toll-like receptor 4 - Cancer Cell InternationalBackground Chemotherapy resistance is an important bottleneck affecting the efficacy of chemotherapy in colon cancer. Therefore, improving the chemotherapy sensitivity of colorectal cancer cells is of great significance for improving the prognosis of patients with colon cancer. Methods CCK-8 assay was employed to examine the cell viability of colorectal cancer cell lines. Realtime-PCR and western blot were used to explore toll-like receptor 4 (TLR4) expression in colorectal cancer cell lines. The functions of TLR4 in the stemness of the colorectal cancer cell lines were analyzed by infecting cells with lentivirus containing TLR4 siRNA. Results We found that aspirin could effectively enhance the chemosensitivity of CT26 and HCT116 colorectal cancer cell lines. Aspirin can also inhibit the stemness of colorectal cancer cell including inhibiting the number of clone formation and reducing the volume and number of cell spheres and inducing the down-regulation of stemness-related genes. Besides that, aspirin also lead to down-regulation of TLR4 expression in colorectal cancer cells. The TLR4 positive colorectal cancer cells demonstrated a higher chemotherapy resistance potential than TLR4 negative colorectal cancer cells. In addition, the stemness of TLR4 positive colorectal cancer cells is stronger than TLR4 negative colorectal cancer cells. Conclusion The results of our study indicate that aspirin increases chemosensitivity of colorectal cancer cells and inhibits the expression of toll-like receptor 4.
Source: BioMedCentral - 🏆 22. / 71 Read more »
Your Favourite Hangover Food May Increase Cancer Risk, New Research SuggestsCereals, bread, ice cream and (sob) supermarket biscuits are not looking so good right now.
Source: HuffPostUK - 🏆 108. / 51 Read more »
£30,000 donation to fund brain cancer research in PrestonSharon Hacking and her daughter Jo from Inbetweenears presenting a cheque to students and staff from the School of Pharmacy and Biomedical Sciences at UCLan UCLan Brilliant such great cause 👏👏👏
Source: blogpreston - 🏆 82. / 55 Read more »
Development and validation of an AI-enabled digital breast cancer assay to predict early-stage breast cancer recurrence within 6 years - Breast Cancer ResearchBackground Breast cancer (BC) grading plays a critical role in patient management despite the considerable inter- and intra-observer variability, highlighting the need for decision support tools to improve reproducibility and prognostic accuracy for use in clinical practice. The objective was to evaluate the ability of a digital artificial intelligence (AI) assay (PDxBr) to enrich BC grading and improve risk categorization for predicting recurrence. Methods In our population-based longitudinal clinical development and validation study, we enrolled 2075 patients from Mount Sinai Hospital with infiltrating ductal carcinoma of the breast. With 3:1 balanced training and validation cohorts, patients were retrospectively followed for a median of 6 years. The main outcome was to validate an automated BC phenotyping system combined with clinical features to produce a binomial risk score predicting BC recurrence at diagnosis. Results The PDxBr training model (n = 1559 patients) had a C-index of 0.78 (95% CI, 0.76–0.81) versus clinical 0.71 (95% CI, 0.67–0.74) and image feature models 0.72 (95% CI, 0.70–0.74). A risk score of 58 (scale 0–100) stratified patients as low or high risk, hazard ratio (HR) 5.5 (95% CI 4.19–7.2, p | 0.001), with a sensitivity 0.71, specificity 0.77, NPV 0.95, and PPV 0.32 for predicting BC recurrence within 6 years. In the validation cohort (n = 516), the C-index was 0.75 (95% CI, 0.72–0.79) versus clinical 0.71 (95% CI 0.66–0.75) versus image feature models 0.67 (95% CI, 0.63–071). The validation cohort had an HR of 4.4 (95% CI 2.7–7.1, p | 0.001), sensitivity of 0.60, specificity 0.77, NPV 0.94, and PPV 0.24 for predicting BC recurrence within 6 years. PDxBr also improved Oncotype Recurrence Score (RS) performance: RS 31 cutoff, C-index of 0.36 (95% CI 0.26–0.45), sensitivity 37%, specificity 48%, HR 0.48, p = 0.04 versus Oncotype RS plus AI-grade C-index 0.72 (95% CI 0.67–0.79), sensitivity 78%, specificity 49%, HR 4.6, p | 0.001 versus Oncotype
Source: BioMedCentral - 🏆 22. / 71 Read more »
Boosting anti-cancer antibodies by reducing their gripNew research from the Centre for Cancer Immunology at the University of Southampton, published ahead of World Cancer Day (February 4), has shown that changing how tightly an antibody binds to a target could improve treatments for cancer.
Source: medical_xpress - 🏆 101. / 51 Read more »
Scientists create more efficient CAR immunotherapies using a molecular anchorAdding a molecular anchor to the key protein used to recognize cancer in cellular immunotherapies can make the treatments significantly more effective. Scientists at St. Jude Children's Research Hospital found that immune cells with the anchored protein increased cancer killing, regardless of their cell type or the kind of cancer targeted.
Source: medical_xpress - 🏆 101. / 51 Read more »